<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html>
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
  <meta http-equiv="Content-Style-Type" content="text/css">
  <title></title>
  <meta name="Generator" content="Cocoa HTML Writer">
  <meta name="CocoaVersion" content="2487.7">
  <style type="text/css">
    p.p3 {margin: 0.0px 0.0px 12.0px 0.0px; font: 12.0px Times; -webkit-text-stroke: #000000; min-height: 14.0px}
    span.s1 {font-kerning: none}
  </style>
</head>
<body>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;!DOCTYPE html&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;html lang="en"&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;head&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;meta charset="UTF-8"&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;meta name="viewport" content="width=device-width, initial-scale=1.0"&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;title&gt;Semaglutide Study Summary&lt;/title&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;style&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>body {</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>font-family: Arial, sans-serif;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>line-height: 1.6;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>margin: 20px;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>background-color: #f4f4f4;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>color: #333;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>}</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>h1, h2 {</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>color: #333;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>}</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>ul {</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>margin: 0 0 20px;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>}</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>li {</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>margin-bottom: 10px;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>}</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>strong {</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">            </span>font-weight: bold;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>}</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;/style&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;/head&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;body&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;h1&gt;Study Summary: Semaglutide Significantly Reduces Mortality and Renal Risk in Diabetic Nephropathy (Phase III)&lt;/h1&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000; min-height: 29.0px"><span class="s1"><b><span class="Apple-converted-space">    </span></b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;h2&gt;Design&lt;/h2&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Phase III FLOW trial, 3,533 patients in 28 countries, with a quarter of the cohort in Europe.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Diabetic patients at high or very high renal risk, with a mean estimated glomerular filtration rate (eGFR) of 47 ml/min/1.73 m² and macro-albuminuria in the majority.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Almost all (95%) were already treated with RAAS inhibitors, but only 15.6% with SGLT2 inhibitors.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;/ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000; min-height: 29.0px"><span class="s1"><b></b></span><br></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;h2&gt;Results&lt;/h2&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;After one year of weekly subcutaneous injection of semaglutide, a statistically significant &lt;strong&gt;24% reduction&lt;/strong&gt; in the risk of major renal events (eGFR halved, renal failure and/or death from renal or cardiovascular causes) was observed, demonstrating the efficacy of treatment in preventing these events.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Results for cardiovascular benefits associated with semaglutide: &lt;strong&gt;29% reduction in cardiovascular mortality&lt;/strong&gt; and &lt;strong&gt;18% reduction in the risk of major cardiovascular events&lt;/strong&gt; (MACE, including death, heart attack, and stroke).&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;In terms of renal endpoints assessed separately, treatment had a significant effect only on patients' risk of having their eGFR halved, with this risk reduced by &lt;strong&gt;27%&lt;/strong&gt; over one year.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;All-cause patient mortality was significantly reduced by &lt;strong&gt;20%&lt;/strong&gt; with semaglutide, with one-year mortality of &lt;strong&gt;12.8%&lt;/strong&gt; in the treatment group versus &lt;strong&gt;15.8%&lt;/strong&gt; in the control group, i.e., almost one patient in six.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Effect on patients' eGFR. Over a four-year follow-up period, treated patients experienced a drop of only &lt;strong&gt;2.19 ml/min/1.73 m²&lt;/strong&gt; per year, compared with an annual drop of &lt;strong&gt;3.36 ml/min/1.73 m²&lt;/strong&gt; in control patients, and the difference was significant. The GLP-1 analogue also reduced patients' albuminuria.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;/ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000; min-height: 29.0px"><span class="s1"><b></b></span><br></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;h2&gt;Conclusion&lt;/h2&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;&lt;strong&gt;FLOW&lt;/strong&gt; demonstrates "clear positive efficacy" of semaglutide in diabetics at high renal risk, and this molecule could constitute a new pillar in the treatment of diabetic nephropathy, alongside RAAS inhibitors, SGLT2 inhibitors, and the selective mineralocorticoid receptor antagonist finerenone (Kerendia*, Bayer).&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;By demonstrating for the first time that semaglutide significantly reduces mortality, renal risk, and cardiovascular risk in chronic kidney disease associated with diabetes, this study confirms that the GLP-1 analogue semaglutide has many benefits that go beyond its primary use as a simple anti-diabetic.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">        </span>&lt;li&gt;Further randomized studies on the subject will be needed, in particular to obtain more precise data on the combination of GLP-1 analogue and/or SGLT2 inhibitor and/or mineralocorticoid receptor antagonist, and thus perhaps demonstrate even better benefits.&lt;/li&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b><span class="Apple-converted-space">    </span>&lt;/ul&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;/body&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000"><span class="s1"><b>&lt;/html&gt;</b></span></h1>
<h1 style="margin: 0.0px 0.0px 16.1px 0.0px; font: 24.0px Times; -webkit-text-stroke: #000000; min-height: 29.0px"><span class="s1"><b></b></span><br></h1>
<p class="p3"><span class="s1"></span><br></p>
</body>
</html>
